Search

Author/Creator Rota-Scalabrini, Delia

1. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. Issue 1 (January 2023)

Authors:
Mina, Roberto; Musto, Pellegrino; Rota-Scalabrini, Delia; Paris, Laura; Gamberi, Barbara; Palmas, Angelo; Aquino, Sara; de Fabritiis, Paolo; Giuliani, Nicola; De Rosa, Luca; Gozzetti, Alessandro; Cellini, Claudia; Bertamini, Luca; Capra, Andrea; Oddolo, Daniela; Vincelli, Iolanda Donatella; Ronco...
Journal:
Lancet oncology
Issue:
Volume 24:Issue 1(2023)
Page Start:
64
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Issue 12 (December 2021)

Authors:
Gay, Francesca; Musto, Pellegrino; Rota-Scalabrini, Delia; Bertamini, Luca; Belotti, Angelo; Galli, Monica; Offidani, Massimo; Zamagni, Elena; Ledda, Antonio; Grasso, Mariella; Ballanti, Stelvio; Spadano, Antonio; Cea, Michele; Patriarca, Francesca; D'Agostino, Mattia; Capra, Andrea; Giuliani, Ni...
Journal:
Lancet oncology
Issue:
Volume 22:Issue 12(2021)
Page Start:
1705
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗